blank
blank

Reflection on clinical and methodological issues in rare disease clinical trials

1:1
Experts provide a comprehensive reflection on the unique clinical and methodological challenges inherent in designing and executing trials for rare diseases.

This paper discusses the specific hurdles faced in rare disease research, including small patient populations and recruitment difficulties. It reflects on innovative trial designs and statistical methods that can enhance the robustness of clinical evidence in these settings.

Acces this publication (pdf)
orphanet

Source

Orphanet Journal of Rare Diseases

Link to cite

Acces to Link >

You might also be interested in

P.Sudara - Undiagnosed Day 2026

In Gdańsk, Undiagnosed Day showed why diagnosis is both a scientific and a human challenge

Bringing clinicians, researchers, patient representatives and families together, the event examined how shorter diagnostic pathways depend not only on better tests, but on shared expertise, structured phenotyping and patient-centred support.
ERDERA and european genomic data infrastructure

Strategic collaboration between GDI and ERDERA

ERDERA and the European Genomic Data Infrastructure have signed a Memorandum of Understanding to strengthen collaboration on secure cross-border access to genomic, clinical and other health-related data, supporting rare disease research and the development of personalised medicine in Europe.
Bojana Mirosavljevic

“Patients are the glue that keeps all other stakeholders together—without them, the system simply does not exist”

ERDERA interviews Bojana Mirosavljevic, scientist and founder of the Život/Life association in Serbia; and one of the country’s leading voices rare disease patient advocacy.
Radka Kaneva and Petia Stratieva, Sofia, March 2026

“National Mirror Groups are essentially a bridge — bringing European developments, standards and opportunities to clinicians and researchers.”

ERDERA interviews Prof. Radka Kaneva and Dr Petia Stratieva, two leading members of Bulgaria’s National Mirror Group (NMG), to explore how the country is working to align its rare disease ecosystem with European developments.

ERDERA's

search form